Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More News From fortuneweek.com

Gains by banks, technology firms lead US stocks higher

Oct 20, 2017

Technology companies and banks led U.S. stocks higher in late-afternoon trading Friday, placing the market on course to extend its gains for the week. Investors cheered a crop of strong company earnings. They also drew encouragement from the Senate's passage of a budget bill, a move expected to ease the path for the White House's tax cut proposal. Consumer products companies lagged the most. KEEPING SCORE: The Standard & Poor's 500 index rose 11 points, or 0.5 percent, to 2,573 as of 3:10 p.m. Eastern time. The Dow Jones industrial average gained 130 points, or 0.6 percent, to 23,293. The...

Rio Olympic head leaves prison; will face corruption charges

Oct 20, 2017

RIO DE JANEIRO — Carlos Nuzman, who headed last year's Rio de Janeiro Olympics, left prison Friday after his arrest two weeks ago on eventual charges that he arranged bribes to land the games for Brazil. The 75-year-old Brazilian is to stand trial for money laundering, tax evasion, and racketeering, though it's unclear how long that will take under Brazil's slow-moving justice system. Brazilian and French authorities say Nuzman helped direct about $2 million to Papa Massata Diack to win votes to land the 2016 Olympics. In the 2009 vote by the International Olympic Committee, Lamine Diack — Papa Massata...

Killer of Navajo Nation girl set to get life prison sentence

Oct 20, 2017

ALBUQUERQUE, N.M. — A man who pleaded guilty to the murder and sexual assault of an 11-year-old girl on the largest American Indian reservation is expected to receive a life prison sentence. Tom Begaye was scheduled Friday to receive the sentence under a plea agreement for the May 2016 killing. The case prompted calls to expand the Amber Alert system and the death penalty to U.S. tribal communities. Authorities have said Begaye lured Ashlynne Mike and her brother into his van in May 2016 before he killed the girl and let the boy escape. Ashlynne was reported missing but an...

AP-NORC poll: Vegas shooting doesn't change opinions on guns

Oct 20, 2017

ATLANTA — A new poll finds that the slaying of five dozen people at a Las Vegas music festival did little to change American opinion about gun laws. In the survey from The Associated Press-NORC Center for Public Affairs Research, 61 percent said the country's gun laws should be tougher, while 27 percent would rather see them remain the same and 11 percent want them to be less strict. That's similar to the results of an AP-GfK poll in July 2016. The new poll found the country divided much more evenly on whether restricting firearms would reduce the number of...

Parole board rejects condemned Ohio inmate's mercy request

Oct 20, 2017

COLUMBUS, Ohio — The Ohio Parole Board on Friday rejected a request for mercy from a condemned inmate who argues he had such a bad childhood and is in such poor health that he should be spared from execution next month. The board's 11-1 decision came in the case of Alva Campbell, set to die by lethal injection on Nov. 15 for killing a teen during a 1997 carjacking. The slaying came five years after he was paroled on a different murder charge. Republican Gov. John Kasich has the final say. The board concluded that Campbell's upbringing and childhood experiences...